Related Experiment Video

Updated: Jan 27, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.2K

PTEN Mutations Trigger Resistance to Immunotherapy

Feixiong Cheng1, Charis Eng2

  • 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.

Trends in Molecular Medicine
|April 1, 2019
PubMed

Insights

Immune checkpoint inhibitors (ICIs) show promise in cancer treatment, but resistance is common. A study found that PTEN gene mutations in glioblastoma patients create an immunosuppressive tumor environment, leading to resistance against ICIs.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Immune checkpoint inhibitors (ICIs) are a cornerstone of modern cancer therapy, targeting pathways like PD-1/PD-L1 and CTLA-4 to reinvigorate anti-tumor immune responses.
  • Despite their efficacy, a significant proportion of patients develop primary or acquired resistance to ICIs, limiting their clinical benefit.
  • Understanding the molecular mechanisms underlying ICI resistance is crucial for developing effective therapeutic strategies.

Discussion:

  • This study investigates the role of somatic PTEN mutations in glioblastoma (GBM) and their impact on the tumor microenvironment (TME) and response to ICIs.
  • PTEN loss-of-function mutations were found to promote an immunosuppressive TME, characterized by altered immune cell infiltration and cytokine profiles.
  • The findings suggest that PTEN status is a potential biomarker for predicting ICI response in GBM.

Key Insights:

  • Somatic PTEN mutations are significantly associated with resistance to immune checkpoint inhibitors in glioblastoma patients.
  • PTEN mutations contribute to resistance by creating an immunosuppressive tumor microenvironment.
  • Targeting PTEN or modulating the immunosuppressive TME may overcome ICI resistance.

Outlook:

  • Further research is needed to elucidate the precise molecular pathways linking PTEN mutations to TME alterations and ICI resistance.
  • Developing combination therapies that target both tumor genetics (e.g., PTEN) and immune checkpoints could improve treatment outcomes.
  • Investigating PTEN status in other cancer types may reveal broader implications for ICI therapy resistance.
Keywords:
PTENcombination therapyglioblastomasimmune checkpointimmunotherapy resistance

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.3K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.7K

Related Concept Videos

Mutations01:39

Mutations

Overview
94.4K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.2K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
63.6K
Mutations in Microorganisms01:18

Mutations in Microorganisms

Mutations are heritable changes in an organism’s genome involving alterations in the base sequence of DNA or RNA. These changes can influence cellular processes and phenotypic traits, potentially transforming the unaltered wild type into a mutant form. Such changes, termed forward mutations, are pivotal in shaping the genetic diversity of organisms.RNA viruses exhibit the highest mutation rates due to the absence of robust proofreading mechanisms during genome replication. In contrast,...
645